Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02478164 · ClinicalTrials.gov registry record · Phase 2

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

A Phase 2 study of Glioblastoma, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
2
Study locations

NCT02478164 is a Phase 2 study of Glioblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02478164, a Phase 2 study of Glioblastoma, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.

Conditions Studied

Glioblastoma

Interventions

  • DRUG Ponatinib

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-07-13
Est. Completion 2018-05-09
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02478164

The ClinicalTrials.gov registry entry for NCT02478164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Ponatinib is the first listed.

NCT02478164 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02478164 about?

NCT02478164 is a clinical study titled "Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma". This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.

What is the current status of trial NCT02478164?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-07-13. Estimated completion is 2018-05-09.

What conditions does trial NCT02478164 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT02478164?

The interventions under investigation include: Ponatinib (DRUG).

Who is sponsoring clinical trial NCT02478164?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02478164 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.